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Abstract
Background: One of the most common and efficient methods for detecting mutations in genes is
PCR amplification followed by direct sequencing. Until recently, the process of designing PCR
assays has been to focus on individual assay parameters rather than concentrating on matching
conditions for a set of assays. Primers for each individual assay were selected based on location and
sequence concerns. The two primer sequences were then iteratively adjusted to make the
individual assays work properly. This generally resulted in groups of assays with different annealing
temperatures that required the use of multiple thermal cyclers or multiple passes in a single thermal
cycler making diagnostic testing time-consuming, laborious and expensive.
These factors have severely hampered diagnostic testing services, leaving many families without an
answer for the exact cause of a familial genetic disease. A search of GeneTests for sequencing
analysis of the entire coding sequence for genes that are known to cause muscular dystrophies
returns only a small list of laboratories that perform comprehensive gene panels.
The hypothesis for the study was that a complete set of universal assays can be designed to amplify
and sequence any gene or family of genes using computer aided design tools. If true, this would
allow automation and optimization of the mutation detection process resulting in reduced cost and
increased throughput.
Results: An automated process has been developed for the detection of deletions, duplications/
insertions and point mutations in any gene or family of genes and has been applied to ten genes
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known to bear mutations that cause muscular dystrophy: DMD; CAV3; CAPN3; FKRP; TRIM32;
LMNA; SGCA; SGCB; SGCG; SGCD. Using this process, mutations have been found in five DMD
patients and four LGMD patients (one in the FKRP gene, one in the CAV3 gene, and two likely
causative heterozygous pairs of variations in the CAPN3 gene of two other patients). Methods and
assay sequences are reported in this paper.
Conclusion: This automated process allows laboratories to discover DNA variations in a short
time and at low cost.
Background
This study focused on ten muscular dystrophy genes
described in Online Mendelian Inheritance in Man [1],
(Table 1); however the resulting process can be applied to
any gene or family of genes.
There are over 40 primary congenital muscle disorders
(Additional file 1) determined now more by the defective
genes causing the disorders rather than specific clinical
descriptions. Many of these diseases are rare. The inci-
dence, defined as the number of new cases per million live
births, (or alternatively as the fraction of live births repre-
sented by one new case) is not known for many of the
more rare diseases; nevertheless, these primary muscle
disorders can be subdivided into three groups in which
estimates of incidence based on published data can be
deduced (Table 2).
The most common form of muscular dystrophy is X-
linked Duchenne muscular dystrophy (DMD) with
approximately 1 in 4200 newborn males affected per year
worldwide [2-5]. Allelic to DMD, the milder form called
Becker muscular dystrophy (BMD) is the second most
common form of the disease. Together DMD and BMD
affect approximately 1 in 3600 newborn males per year
worldwide [4] and compose nearly 80% of all new cases
of dystrophy and 56% of all new cases of congenital
myopathy of all types. Female carriers of DMD/BMD are
born with approximately the same frequency as male
patients [6,7]. The underlying cause of DMD and BMD
was identified over 20 years ago [8-10] as abnormalities of
the DMD gene, encoding the protein named dystrophin.
Approximately 60% of DMD and BMD cases are caused
by large deletions (one exon or greater) or large duplica-
Table 1: OMIM and Accession numbers
Homo Sapiens
Gene OMIM# Genomic RefSeq NM_# v.* Entrez
Gene ID
UniProt ID
DMD 300377 NC_000023 004006 .2 1756 P11532
CAV3 601253 NG_008797 033337 .1 859 P56539
CAPN3 114240 NG_008660 000070 .2 825 P20807
TRIM32 602290 NG_011619 012210 .3 22954 Q13049
FKRP 606596 NG_008898 024301 .4 79147 Q9H9S5
LMNA 150330 NG_008692 170707 .2 4000 P02545
SGCA 600119 NG_008889 000023 .2 6442 Q16586
SGCB 600900 NG_008891 000232 .4 6443 Q16585
SGCG 608896 NG_008758 000231 .2 6445 Q13326
SGCD 601411 NG_008693 000337 .5 6444 Q92629
OMIM = Online Mendelian Inheritance in Man, NM_# are the RefSeq numbers for the most common muscle isoform mRNA.* version is the latest 
NM_# version at time of publication and also the version used for CDS nucleotide numbering in Table 7 HGVS variation nomenclatureBMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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tions in the DMD gene [11,12]. In the past, when a new
patient was suspected of having some type of muscular
dystrophy, the first molecular test prescribed was the
Chamberlain-Beggs multiplex PCR test [12,13]. This test
detected 98% of large deletions and some duplications in
the dystrophin gene. The test is composed of four groups
of multiplexed PCR assays covering 19 hot spot exons out
of the 79 exons of the DMD gene. Sometimes when the
test detected one or more deleted or duplicated exons,
additional adjacent exons not in the hot spot region had
to be tested separately in order to find the break points
which are important for differentiating BMD from DMD.
This test has now been replaced in most laboratories by
the Multiplex Ligation-Dependent Probe Amplification
(MLPA) test [14] for aberrant copy number in the Duch-
enne muscular dystrophy gene. MLPA tests all 79 exons in
two reactions, (P034-DMD-1 and P035-DMD-2, MRC-
Holland; Willem Schoutenstraat 6; 1057 DN Amsterdam;
The Netherlands) and will detect the exact molecular
cause, including break points, for approximately 60% of
DMD and BMD cases.
Various forms of direct sequencing and exon pre-screen-
ing from patient DNA have been used to detect the major-
ity of the remaining 40% of mutations in the DMD gene.
These remaining mutations are mostly small (less than
one exon) variations collectively known as point muta-
tions [15] including insertions, duplications, deletions,
deletions plus insertions (indels) and single or multiple
base changes. One of the most common and efficient
methods for detecting mutations in the exons and regions
of interest in disease genes is Polymerase Chain Reaction
(PCR) amplification of the area of interest resulting in
millions of copies of that DNA fragment followed by
direct sequencing of the fragment. Until 2003, and even
now, in many laboratories, the process of designing PCR
assays (flanking sense and anti-sense primers to amplify
the regions of interest in DNA) has been to focus on the
individual PCRs and not on the complete set of PCRs to
test a gene or a group of genes. Primers for each individual
PCR were selected primarily based on location and
sequence concerns. Melting temperatures for the two
primers were calculated, followed by attempts to adjust
the primer sequences to nearly match each other's melting
temperature. Finally, annealing temperature for the PCR
was set approximately 5°C below the primer Tm's [16].
This process generally results in groups of assays with var-
ying annealing temperatures requiring either the use of
multiple thermal cyclers or multiple passes in a given ther-
mal cycler. This makes diagnostic testing nearly impossi-
ble to automate and therefore time-consuming, laborious
and expensive.
In 2003, a methodology termed Single Condition Ampli-
fication/Internal Primer (SCAIP) [17] was introduced and
applied to the DMD gene superceding previous method-
ologies such as Detection Of Virtually All Mutations
(DOVAM) [18] and Denaturing High Performance Liquid
Chromatography (DHPLC) [19]. The major advantage of
SCAIP is that all assays are performed at a single set of
thermal cycler conditions in a single multi-well plate.
Among the other advantages of SCAIP is that the use of
internal sequencing primers provides increased specificity
of each assay to the area of DNA under examination. As
published, the SCAIP method uses a series of ethanol
washes for PCR and cycle sequencing reaction purification
and it uses original phred/phrap/consed software [20] for
sequence analysis. One potential drawback to the SCAIP
method is that if a single amplicon does not amplify, pos-
sibly due to polymorphic sequence at the primer site, the
Table 2: Incidence data for three subdivisions of primary muscle disorders
Maximum incidence Minimum incidence Average
Type freq. × 10-6 fraction freq. × 10-6 fraction ×10-6 fraction
DMD/BMD 354 1/2825 186 1/5376 270 1/3703
Other dystrophies 100 1/10000 41 1/24390 70 1/14286
Congenital myopathies 219 1/4566 100 1/10000 160 1/6250
Total 673 1/1486 327 1/3050 500 1/2000
DMD mean incidence is well established at 300 × 10-6 (Emery 2002) but data varies from country to country and survey to survey. It is unlikely to 
be much higher but may be as low as 169 × 10-6 (Cowan 1980). BMD frequency is based on (Emery 1991). Thankfully, both DMD and BMD 
incidence is probably declining annually due to genetic testing and counselling.
Other dystrophy incidence numbers are scarce to non-existent. The rough estimate maximum is extrapolated from (Bushby 2001) and minimum 
from (Emery 2002).
Other congenital myopathy numbers are also scarce to non-existent. The maximum estimate is extrapolated from (Nonaka 2001) as 81% of the 
mean DMD incidence. The minimum estimate is extrapolated from (D'Amico 2008) and (Lopate 2007).
These data were used for estimation of testing cost and should be considered as rough estimates only.BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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assay must be repeated using various combinations of the
PCR and internal sequencing primers. At the time of pub-
lication, SCAIP was applied to the DMD gene only. Many
other forms of congenital myopathies remain with little
or no options for diagnostics. A search of GeneTests [21]
for sequencing analysis of the entire coding sequence for
other myopathy genes aside from DMD returns a small
number of choices at fairly high costs and long turn-
around times. A partial list of available services, costs and
turn-around time (TAT) is summarized in tables 3&4 and
Additional file 2. Therefore in many families a molecular
diagnosis may be difficult or impossible to obtain due to
the lack of relevant tests, high cost, or long turn-around
time of existing tests. This serves as motivation for all cli-
nicians and researchers to offer ever more accurate and
fast diagnostic testing of these diseases that is offered at
low cost to affected families. There is progress in that
direction. In 2006, Tjeldhorn et al. demonstrated a reduc-
tion from 72 hours manual labor in the fully manual
mutation detection processing for 16 Marfan syndrome
patients to 23 hours of manual work in an automated
process reducing testing time from 145 total hours to 67
hours[22]. In addition in 2008, protocols were published
for mutation detection using automated fluorescence-
based sequencing[23,24]. With more than 40 different
primary muscle disorders, a different approach to
sequencing and diagnostics was desperately needed. Early
in 2003, this study began in order to determine if a more
automated and less costly mutation detection process
could be developed expanding the SCAIP concepts to
encompass more genes and also to more fully automate
the process. By taking advantage of some modern compu-
ter aided design tools, the most recent database updates,
and SNP tools, primer sequences were designed that
avoided common simple nucleotide polymorphisms. In
theory, eliminating polymorphisms from primer
sequences enhances the detection of subsequent hetero-
zygous polymorphisms (important for autosomal disor-
ders) and limits the number of assays that need to be re-
amplified using different primers. Due to more careful
designing of primers and avoidance of simple nucleotide
polymorphisms, the technique of using universal
sequencing primers appended to the 5' end of the PCR
primers was enabled. The major benefit of universal
sequencing tails is that it not only enables universal
sequencing reaction conditions for all assays, but also
avoids the necessity of separate internal sequencing prim-
ers simplifying the task of automation. This automation
could be accomplished by taking advantage of improve-
ments in purification techniques (e.g. magnetic beads),
more user friendly sequence analysis tools [e.g. Mutation
Surveyor™ (SoftGenetics, LLC. State College, PA), Seqs-
cape™ (Applied Biosystems Inc. part of Life Technologies,
Carlsbad, CA), Sequencher™ (Gene Codes Inc., Ann
Arbor, MI)], newly available DNA analyzers [e.g. the
QIAxcel™ system (formerly eGene system, QIAGEN Inc.,
Valencia CA)] and robotics [e.g. Hamilton MicroLab Star-
Plus™ (Hamilton Co., Reno, NV)].
Thus a process could be nearly fully automated such that
a technician running the process would only have to pre-
pare master mixes and transport plates between equip-
ment stations in the process. At the conclusion of this
study, at least ten muscular dystrophy genes have one or
more automated mutation detection methods available.
The study's results however can be applied to genes
involved in any inherited disease or trait. Here we report
on the development of the process including assay primer
sequences for ten muscular dystrophy genes (Additional
files 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12), Hamilton MicroLab
StarPlus automated methods (Additional files 13 and 14),
Seqscape templates (Additional files 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25, 26 and 27), PCR recipes and condi-
tions, and patient mutations found.
Table 3: Survey of services available for DMD/BMD point mutations
Laboratory Pricing TAT comments
Athena Dx Worcester, MA $5070.00 6-8 weeks
City of Hope Los Angeles, CA $1860.00 10 weeks
Emory Univ. Atlanta, GA $2313.00 4-6 weeks Resequencing array
CHB* $3634.00 6-8 weeks
U. of Utah $1175.00 6 weeks Negative -del/dup testing required
Data gathered from GeneTests http://www.genetests.org and telephone survey of available services for DMD/BMD point mutation testing. 
*Children's Hospital Boston current testing based on DHPLC method, UCDS not yet priced
(Note that the survey was done in April, 2009 and the services fortunately are constantly being expanded and improved.)BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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Results
Primer design
Primers were designed using computer aided design tools
such as OLIGO™ (Molecular Biology Insights, Inc., Cas-
cade, CO), and by using the ever improving BLAST and
SNP features of public and private databases such as
SNPbrowser™ [25], NCBI dbSNP [26], Ensembl [27],
Lieden [28], NCBI/BLAST[29], UCSC [30], HapMap [31]
and others. Amplicon size was targeted for 600 bases for
best sequencing results but this was not always possible
due to exon size, polynucleotide strings greater than 7
bases or GC rich clusters greater than 5 bases which do not
sequence well. Assays could be designed for all regions of
interest in most genes with enough specificity and lack of
common polymorphisms within the primer sequences to
avoid the necessity of internal primers and to allow for the
use of universal sequencing primers appended 5' to the
PCR primers. This resulted in assays (including a universal
forward and reverse sequencing tail) associated with a
gene or gene family that would all amplify and sequence
efficiently at a universal set of conditions. In some
instances, in collaboration with Applied Biosystems Inc.,
primers from the VariantSeqR™ (Applied Biosystems Inc.
part of Life Technologies, Carlsbad, CA) product line were
validated The sequences of VariantSeqR assays are availa-
ble on the NCBI web page [32]. Simultaneously, automa-
tion tools and methods were evaluated or developed
(Additional files 28, 29, 30, 31, 32, 33, 34, 35 and 36).
Amplification optimization
Robust amplification was achieved after multiple experi-
ments with PCR polymerases, plate seals, 384 well PCR
plates, and automated liquid handlers from various ven-
dors. PCR polymerase kits from five vendors were tested
to determine which kit would represent the highest prob-
ability of success over a wide range of target sequence var-
iability. Two vendor polymerase kits failed in early
experiments due to weak bands having less than 2.0 ng/uL
of product DNA (data not shown). Three more were then
tested including polymerase C, Roche FastStart (FS) and
polymerase D against a subset of 8 assays (Figure 1).
Roche FastStart efficiently amplified all eight assays and
was chosen for all future experiments. Early in the study
there was significant evaporation from wells of the 384-
well plates probably due to inefficient seals that were
being used at the time. After experimenting with BioRad
MSB1001 and Applied Biosystems 4306311 the results
indicated that neither allowed well contents to evaporate
when carefully applied using an adhesive film applicator
(Applied Biosystems part # 4333183). Choice of PCR
plate is important both for success of amplification and
for compatibility with automation equipment. After
experiments with plates from a few vendors, Thermo
Fisher Scientific Inc. part #AB1111 plates were chosen for
our automated process. After much investigation of liquid
handling systems, Hamilton MicroLab StarPlus was cho-
sen for the process. Results have been very consistent as
measured by spot checking amounts pipetted. After using
agarose gels and other DNA analysis systems, the QIAxcel,
an automated 12-channel capillary electrophoresis sys-
tem, was chosen for deletion/duplication detection and
for PCR product quantification due to its automation of
the process, superior accuracy and ease of use. PCR reac-
tion volumes of 24, 12, 6, and 3 uL were compared over 8
assays. No reactions worked at 3 uL, but all worked at 6 uL
Table 4: Survey of services available for LGMD gene mutations
Laboratory Gene Panel Genes Tested Pricing TAT
Athena Dx Worcester, MA Yes
(9 genes)
CAPN3, SG's, DYSF, CAV3, FKRP, LMNA $10,790.00
(total)
5-6 weeks
Nationwide Children's Ohio State No CAPN3, SG's, DYSF, CAV3, FKRP, LMNA $874.50-$1790.75 (per gene)
(varies by size)
4 weeks
Prevention Genetics Marshfield, WI No CAPN3, DYSF, FKRP, LAMA2, SGCA, SGCB
(6 genes singly sequenced)
$390.00-$2990.00
(per gene)
(varies by size)
40 days/gene
U. of Utah Yes (2 genes) DYSF & CAPN3 $1500.00
(total)
8 weeks
U of Iowa Yes (3 genes)
(panel)*
SGCA, SGCB, FKRP
CAPN3, LMNA, FKRP, POMT1, POMT2, 
POMGnT, FCMD**
$905panel*
$462-1781
(per gene)
(varies by size)
2-4 wks
Data gathered from GeneTests http://www.genetests.org and telephone survey of available services for LGMD gene testing. * The U of Iowa panel 
tests for three known mutations only, if none is positive then the entire FKRP gene is sequenced. **7 genes singly sequenced. (Note that the survey 
was done in April, 2009 and the services fortunately are constantly being expanded and improved.)BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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though some were below design goal concentrations of
PCR product (data not shown). The 12 uL reaction vol-
ume was chosen for our automated process because we
wanted the smallest volume possible in order to reduce
costs but were not yet confident enough in the 6 uL vol-
ume.
Assay optimization and verification
A total of 309 assays spanning ten known muscular dys-
trophy causing genes have been designed and/or verified
to date and are laid out in three plates (Table 5).
All 309 assays were verified by performing PCR using
unaffected control DNA, analyzing the products of PCR
using the QIAxcel, and by sequencing those products in
the ABI 3730 DNA Analyzer™ sequencer (Applied Biosys-
tems Inc. part of Life Technologies, Carlsbad, CA). Assay
design was an iterative process. For example, of 45 assays
designed in-house, 35 were successful on first trial and did
not require redesign (78% success on first trial), and of the
10 remaining which were redesigned, eight were success-
ful on their first trial and did not require additional rede-
sign (80% success on first trial of these 10 redesigned
primers). The final two unsuccessful assays were rede-
signed again, and both were successful (100% success for
these last two designs). Therefore, even when using com-
puter aided design tools, the process of designing success-
ful assays is still iterative. An example of QIAxcel data is
presented in Figure 2 and Table 6 for the CAV3 gene and
in Additional files 37, 38, 39 and 40 for the DMD gene.
Sequence quality and detection of heterozygosity
Sequence data from both the sense and anti-sense direc-
tion of each amplicon (the sequence between the two PCR
primers of the assay) was analyzed using the software
application Mutation Surveyor and/or SeqScape and/or
Sequencher. All three provide quality scores for each base
read using a proprietary algorithm developed starting
from original phred/phrap/consed software. As an exam-
ple of typical quality of sequence, for the 2490 bases of
coding region of the CAPN3 gene for patient 1092.1, 2401
bases had quality scores above 25 (range 0-50) (96.4%),
82 bases had quality scores between 15 and 25 (3.3%)
and 7 bases had quality scores below 15 (0.3%). Sensitiv-
ity in detection of autosomal heterozygosity is illustrated
in Additional file 41: Figures One, Two, Three and Four.
The detection of a heterozygous deletion/insertion muta-
tion requires that the reviewer must be vigilant in recog-
nizing and deciphering when the sequence is high quality
(that is clean separated peaks for each base with low back-
ground noise and high quality scores) up to a point from
left to right and also high quality [or in the particular case
of Additional file 41: Figure Three, acceptable quality (i.e.
although the quality scores are lower for each peak and
the background noise is higher, each peak is still separate
and well above background)] up to the same point from
right to left. This is usually indicative of an insertion (or
duplication) or deletion often of just one or a few bases
on one allele only. This situation is illustrated in Addi-
tional file 41: Figures Three and Four for patient 1102.1.
The analyst should also use simple nucleotide polymor-
phism information to help determine heterozygosity of
each allele. As can be seen in Figure One of Brockington et
al[33], heterozygous variations can either be detected or
easily overlooked.
Using assays that meet the goals specified in the Methods
section, five suspected DMD patients who had tested neg-
ative for large deletions or duplications in tier 1 testing
(MLPA) and 13 additional patients with muscular dystro-
phies of unknown etiology were tested. Mutations were
found in the DMD gene of the five suspected DMD
patients and in four non-DMD/BMD patients with an ini-
tial diagnosis of limb-girdle muscular dystrophy (LGMD)
of unknown etiology including the following: one FKRP,
one CAV3, and two likely causative pairs of variations in
the CAPN3 gene of two patients (Table 7).
Costs and Turn-Around Time
Reagent costs will vary in near direct proportion to PCR
and sequencing reaction sizes. The goal is to reduce these
reaction sizes to as small as possible while remaining con-
sistent with sequence and gene coverage goals. Table 8 in
the methods section presents an estimate of reagent and
plastic (consumables) costs based on 12 uL PCR and 10
uL sequencing reaction volumes. The resulting consuma-
Polymerase trial experiments Figure 1
Polymerase trial experiments. lane 1 DNA ladder, lanes 
2-4 are DMD assay #1 lane 2 polymerase C (PC), lane 3 
Roche FastStart (FS), lane 4 polymerase D (PD) lanes5-7 are 
DMD assay #1a lane 5 PC, lane 6 FS, lane 7 PD, lanes 8-10 
are DMD assay #1b lane 8 PC, lane 9 FS, lane 10 PD, lanes 
11-13 are DMD assay #2 lane 11 PC, lane 12 FS, lane 13 PD, 
lanes 14-16 are DMD assay #4 lane 14 PC, lane 15 FS, lane 16 
PD, lanes 17-19 are DMD assay #10 lane 17 PC, lane 18 FS, 
lane 19 PD, lanes 20-22 are FKRP assay #24 lane 20 PC, lane 
21 FS, lane 22 PD, lanes 23-25 are FKRP assay #21 lane 23 
PC, lane 24 FS, lane 25 PD.BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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Table 5: Genes covered to date
Plate Protein Phenotype # exons # Assays
Genes
PLATE #1
DMD dystrophin Duchenne/Becker 79 128
PLATE #2
CAV3 caveolin LGMD 1C 2 11
FKRP fukutin related LGMD 2I(CMD) 4 18
CAPN3 calpain3 LGMD 2A 30 52
TRIM32 tripartate contain32 LGMD 2H 3 15
PLATE #3
SGCA sarcoglycan alpha LGMD 2D 10 13
SGCB sarcoglycan beta LGMD 2E 6 20
SGCG sarcoglycan gamma LGMD 2C 8 20
SGCD sarcoglycan delta LGMD 2F 10 17
LMNA lamin a/c LGMD 1B(EDMD) 12 15
Lists the genes covered by plates 1 through 3, the proteins coded by those genes, the associated phenotype when the gene is mutated, the number 
of exons and assays associated with each gene.
Table 6: QIAxcel spreadsheet of size and concentration data
Assay Name CV01 CV02 CV15 CV10 CV19 CV12
size (bp) 621.3 581.4 605.9 627.7 489.3 332.4
conc. (ng/uL) 8.13 8.07 7.05 2.77 6.7 5.49
Assay Name CV11 CV06 CV16 CV08 CV13
size (bp) 594.7 609.5 507.3 537/566 208.9
conc. (ng/uL) 18.97 6.77 9.02 4.64/2.78 13.35
Compare to Figure 2: QIAxcel gel image CAV3 assaysBMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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bles cost per patient for plate 1 is $532.00 and for plate 2
is $395.00. One approach to pricing the service would be
to average the price per patient over a typical mix of 100
muscular dystrophy patients across all five tiers of testing.
Using this approach the resulting averaged price obtained
from the calculations in the methods section for a typical
patient sample is $1040.00 for direct labor plus consum-
ables.
The sample processing labor hours estimate (16 hours per
patient), also provided in the methods section, for each
tier of tiers 2-4 is conservative for steady state continuous
processing with dedicated equipment including one auto-
mated liquid handler, two 96 capillary sequencers, three
QIAxcel systems and four 384-well PCR blocks.
Turn-around time for a particular individual would be less
than one week in steady state continuous processing
mode. However, in stop and start mode with tasks other
than sample processing interleaved, the turn-around time
would be much longer.
Discussion
By optimizing the primer design, reaction conditions and
automation of the process, a cost effective and sensitive
approach to sequencing of multiple genes involved in an
overlapping set of muscle degenerative disorders has been
developed. Results of experiments done during this study
show that not all polymerases, plate sealing films, multi-
well plates, liquid handling systems, PCR reaction vol-
umes and DNA analysis systems are created equal, and
that care must be taken in choosing or changing any of
these variables as they can have a major impact on suc-
cessful implementation as well as cost. However, the prin-
ciple question to be answered by this study was whether
or not the use of up to date human genome information
including simple nucleotide polymorphisms available in
various databases and computer aided design tools would
allow the design of specific assays that would PCR amplify
and cycle sequence at a universal set of conditions. Note
that it is wise when designing primers for PCR assays,
especially for amplification of regions of interest in the
human genome, to take into account simple nucleotide
polymorphisms which include Single Nucleotide Poly-
morphism (SNPs), as well as Deletion/Insertion Polymor-
phism (DIPs or INDELs), Short Tandem Repeat
(microsatellite) Polymorphism (STRs), and Multiple
Nucleotide Polymorphism (MNPs). This is true because if
the chromosome/patient being assayed is homozygous
for the minor allele, the primers may not bind as well,
which, depending on the location of the polymorphism
within the primer may decrease the efficiency and sensi-
tivity of the assay either minimally or severely. Of greater
concern when screening for heterozygous mutations in
autosomal disorders or genotyping is that if the patient/
chromosome is heterozygous, the primer will hybridize
more efficiently to the strand carrying the major allele and
produce allele specific amplification results. Subsequent
sequencing or genotyping will then fail to detect hetero-
zygous bases within the amplicon and may cause the
reviewer to falsely rule out a candidate gene or mutation.
Data from this study indicates that a nearly fully auto-
QIAxcel gel image CAV3 assays Figure 2
QIAxcel gel image CAV3 assays. Columns 1 through 11 contain PCR products from control DNA for CAV3 assays. The 
15 base pair and 3000 base pair bands are reference markers injected before the PCR products are injected. Note that the 
46XY control DNA that was used may be heterozygous for assay cv 08. Single bands and good forward sequence for this assay 
in several patients' DNA has been seen. Also there is a large CA repeat in the area which renders the reverse sequence poor. 
See Additional file 8 for size, concentration and gene coverage details.BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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mated and less costly mutation detection process that was
developed for ten genes has the capability to encompass
many more genes, and that internal sequencing primers
(although they do increase specificity) will not be neces-
sary if sufficient care is taken in designing assays. Internal
primers instead of universal sequencing primers, how-
ever, would not be incompatible with this process.
The data also supports the concept that using computer
aided design tools such as Oligo and NCBI/Blast to find
primers that meet all the design criteria of this automated
process (Additional file 42) will increase the percentage of
successful assays that are sensitive to autosomal heterozy-
gosity from roughly 50% attained by simply drawing a
line under 19-24 bases on target sequence (estimate based
on previous experience) to greater than 80%.
The full answer to the question of how effective our auto-
mated process is at finding mutations in patients will only
be evident after a large number of patients have been
tested. To date the data provides a reasonable degree of
optimism and has been recognized as sufficient validation
Table 7: Patient samples tested to date and variations found
Plate # Patient # Gene Variation: DNA experimentally 
determined(protein: theoretically deduced)
Exon/Intron CK value Age of Onset DYS -IHC
1 B1101.1 DMD c [2521C>T] (p.Gln841X) 20 2601 Female->10 y/o N/A
1 9 DMD c.8038C>T(p.Arg2680X) 55 11,010 8 N/A
1 174 DMD c.2614_2615insA (p.?) 20 N/A 6 N/A
1 343 DMD c.829C>T(p.Gln277X) 8 32,000 5 N/A
13 8 3
(BMD)
DMD c.13208_13209ins
ACCTTATGTGACGCTGG
3'UTR 3,935 11 N/A
1 B1105.1 DMD no causative variation found 1500 18
1 B1028.1 DMD no causative variation found 10,000 5 absent
1 1 DMD no causative variation found N/A N/A N/A
1 B646.1 DMD no causative variation found 450 20's
2 B646.1 FKRP c [826C>A]+ [826C>A](p.Leu276>Ile) 4 450 20's
2 B1141.1 CAV3 c [84C>A]+ [=](p.Asp28Glu) 1 2400 37 Normal
2 B1092.1 CAPN3 c [551C>T(+)706G>A] (p.Thr184Met +Ala236Thr) 4,5 289 6 Normal
2 B1102.1 CAPN3 c [550delA(+)1967dupACATTTTCAAGCAG] 4,17 2000 34 faint
2 B1103.1 no causative variation found 9505 1 Normal
2 B112.1 no causative variation found 156 1 Normal
2 B1149.1 no causative variation found 1074 10
2 B122.1 no causative variation found 593 2 Normal
2 B695.1 no causative variation found 321 2-3 Normal
2 B848.1 no causative variation found Normal
Far left column lists the plate number used to test the sample, the next column lists patient sample number, the next column lists the gene in which 
a causative or possibly causative variation was found and the next column lists variations. N/A means data not available. Note that patient samples 
with no causative variation found on one plate may be repeated on another plate, and that patients have not yet been tested against all three plates.BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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to commence use as the clinical process at Children's Hos-
pital Boston. Cost and throughput analysis done in this
study supports the conclusion that the automated process
described herein is a more cost effective and higher
throughput method of mutation detection than manual
direct sequencing.
Troubleshooting amplification and sequencing failures
Regardless of how carefully assays are designed there are
bound to be certain combinations of patient DNA and
assay that will fail to amplify or sequence properly even
when the patient DNA is not deleted or duplicated in the
area being amplified. If this is anything but a rare occur-
rence for a given assay, the assay must be redesigned. For
those rare occurrences, many troubleshooting techniques
do exist. For example, one can retry the assay manually
(on the bench) using the same primers as well as alterna-
tive primers, including positive and negative control tem-
plates. Also many PCR kits contain alternative reagents for
GC rich and AT rich regions of DNA and there is a large
Table 8: Estimated reagent and sequencing costs
Reagent Cost/well Extended cost Plate 1 Extended cost Plate 2 or 3
Assay $0.03
Fast Start $0.34
dNTPs $0.04
10× Buffer $0.02
Sub Total $0.43
X6/5* $0.52
X8/7# $0.49
Plastic ware $0.06 $0.06 $0.06
QIAxcel system $0.25 $0.25 $0.25
AmPure $0.07 $0.07 $0.07
Total PCR
reagents
$0.90/patient PCR $0.87/patient PCR
Big Dye $0.90 $1.80/patient PCRΘ $1.80/patient PCR
Buffer $0.06 $0.12/patient PCR $0.12/patient PCR
Plate $0.01 $0.02/patient PCR $0.02/patient PCR
CleanSeq $0.30 $0.60/patient well $0.60/patient PCR
Plate $0.01 $0.02/patient PCR $0.02/patient PCR
Total per patient well $3.46 $3.43
Total per patient $442.88 $329.28
Add ~20% for waste $532.00 $395.00
* for one negative control per 5 patients on plate 1; # one negative control per 7 patients on plates 2 or 3; Θ for both Forward and Reverse 
sequence/PCR.
20% waste value is a conservative estimate of waste established over many years and used by our clinical and research labs in calculating material 
waste. It includes remaining reagents in large cocktail batches and possible manual repeats.BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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body of literature available for optimization of PCR and
sequencing reactions which may need to be investigated
in rare situations. For example, 1 M final concentration
Betaine and/or 5% final DMSO may be included into the
PCR recipe to assist the polymerase in GC rich sequence
areas. Since this kind of manual troubleshooting will neg-
atively impact TAT and cost, it should be done in the
research and development mode. Only robust well tested
assays should be used in the clinical setting. For occa-
sional rare failures, after a first round of troubleshooting
in the clinical department, the problem assay should be
assigned to the research department to resolve.
Gross and single exon alterations in autosomal genes
Although the spectrum of mutations in the DMD gene is
well established as approximately 60% large alterations
(one exon or greater) and 40% point mutations, it is far
less well established in the remaining nine genes
addressed in this manuscript. A brief review of mutations
found in these genes in the Leiden muscular dystrophy
databases and the literature leads one to believe that the
percentage of large alterations in these genes is less than
15%[34]. Therefore we will test for these types of muta-
tions in tier 5 in patients who have not had mutations
identified in tiers 1 through 4. Tier 5 will consist of MRC-
Holland art. nr. P176-CAPN3, P116-SGC, P048-LMNA/
MYOT, and P268-DYSF (though we have not developed
point mutation assays for DYSF). Although simple nucle-
otide polymorphisms are to be avoided in primer design,
they are beneficial in other portions of the amplicon as
they may assist the analyst in determining the
homozygous, heterozygous or hemizygous status of a par-
ticular allele. Availability of parental and sibling DNA will
of course be especially valuable in this regard.
Implications and the importance of mutation detection
Determining an exact molecular diagnosis is important
for numerous reasons including family planning, carrier
status of extended family, and diagnosis and treatment in
other family members. Physicians can more accurately
determine a prognosis when the type of muscular dystro-
phy and molecular cause is known. Many potential ther-
apy trials involve mutation specific treatment and require
a molecular diagnosis in order to be eligible for participa-
tion. Finally for many patients and families there is a
sense of discontent from not knowing a definitive diagno-
sis of their disease.
Automation of the process and Alternatives to the process
All of the pipetting steps of the process can be accom-
plished manually in either 384-well or 96-well plates
using a multi-channel pipettor. However, manually pipet-
ting into a 384-well plate can be quite tedious and prone
to mistakes while using a 96-well plate probably would
require increasing the PCR reaction volume from 12 μL to
18 μL. Either of these manual approaches would forfeit
the benefits of automation. Suggested layouts for 384-well
plates for tiers 2-4 are available in previously mentioned
additional files. (Note that tier 1 is simply the running of
the MLPA test for DMD large deletions or duplications).
However, any layout that works in a given lab setting
including testing of a single gene at a time is fine and will
require only minor modifications to the Hamilton Micro-
Lab StarPlus methods written for the suggested layouts.
The process we have developed is flexible enough to allow
for improvements. Many alternatives exist for automating
the process and the choice of the proper equipment is cru-
cial to successful implementation. For a list of suggested
evaluation criteria see Additional file 43.
Alternatives to our process are on the horizon as well. For
example, next (or second) generation sequencing [mas-
sively parallel sequencing by synthesis (using probe liga-
tion, single-base extension or pyrosequencing
technology)] promises to be capable of sequencing whole
chromosomes or targeted areas on multiple chromo-
somes in a single sequencing run in the near future.
Also CustomSeq™ Resequencing arrays (Affymetrix Inc.
Santa Clara, CA) offer promise as possibly another alter-
native to come. When this study began in 2003, there were
problems with this technology and it was decided that the
probability of achieving full coverage of each gene at qual-
ity goals specified and at low enough cost per patient was
lower at that time than our process. In the future, with
technological improvements, resequencing arrays may be
a better alternative. Emory University Genetics Laboratory
is currently offering both CGH array and resequencing
array for the DMD gene. A new project involving DNA-
chip arrays is beginning at the TREAT-NMD project team,
at the Institute of Human Genetics, University of Newcas-
tle upon Tyne, United Kingdom and may prove a future
alternative.
Conclusion
Successful assays can be designed using computer aided
design tools which will all amplify at a single set of ther-
mal cycler conditions and sequence at a single set of cycle
sequencing conditions. This enables many assays to be
robotically assembled into a single 384-well plate and
cycled at a universal set of conditions. Due to the automa-
tion and the smaller volumes of the automated process
described herein, the costs and turn-around time of diag-
nostic testing can be reduced significantly from high cur-
rent costs and long lag times, especially for the limb-girdle
muscular dystrophies.
Diagnostic laboratories around the world can now use an
automated process to identify mutations in the ten genes
addressed in this study. This process can be applied usingBMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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techniques described in this paper, the referenced papers
and the additional files to many other genes as well,
including the remaining muscle disease causing genes and
genes involved in other disease families with multiple
causative genes (e.g. Fanconi Anemia and other bone mar-
row failure anemias, Charcot-Marie Tooth Neuropathies,
etc.).
Methods
Assay primers design
Assay primers were designed for all regions of interest
using Oligo, NCBI/SNPdb, NCBI/BLAST, Ensembl, and
other computer aided design tools as well as SeqScape and
Sequencher for an optimum annealing temperature of 58-
60°.
Assay storage and distribution to 384-well plates
Primers were received from the vendor in a 2.0 mL vial in
a lyophilized state with the antisense (Coding, Forward or
Upper) primer and the sense (Non-coding, Reverse or
Lower) primer in separate tubes. Primers were suspended
to 60 μM in warm 25% glycerol and 75% nuclease free de-
ionized water. From these stocks, working assays were pre-
pared in 1.4 mL ScreenMate™ tubes (PN 4247) with
SepraSeal™ caps PN 4464 (Matrix Technology Corp. Hud-
son, N.H.) using 960 μL of 25% glycerol and 20 μL of for-
ward primer 60 μM stock and 20 μL of reverse primer 60
μM stock. This resulted in a solution of 1.2 μM each or 2.4
μM total primer concentration in 25% glycerol. The Ham-
ilton MicroLab StarPlus distributed 6 μL of this assay solu-
tion into the wells of a 384-well plate and the plate was
dried (70°C for 40 min.) to 1.5 μL of pure glycerol at 4.8
μM each or 9.6 μM total primer concentration. Similarly,
the M13F (5'-TGTAAAACGACGGCCAGT-3') and M13R
(5'-CAGGAAACAGCTATGACC-3') primers were ordered
and received in 2.0 mL vials in a lyophilized state in sepa-
rate tubes and suspended to 60 μM in warm 25% glycerol
and 75% nuclease free de-ionized water. From these
stocks working concentrations at 1.8 μM in 25% glycerol
were prepared. All stocks in 25% glycerol can be stored for
short term at 4°C if tightly capped (and perhaps wrapped
in parafilm) and at -20°C if stored for longer than 4
weeks. The Hamilton MicroLab StarPlus distributed 2 μL
of forward or reverse sequencing primer into all wells of a
384-well plate (one plate for M13F and one plate for
M13R), and the plates were dried (70°C for 20 min.) to
0.5 μL of pure glycerol at 7.2 μM concentration. All plates
that contain primers diluted in pure glycerol may be
sealed and stored at room temperature for future use or
used immediately. 1.5 μL of glycerol will not adversely
affect a 12 μL total volume PCR, nor will 0.5 μL of glycerol
adversely affect a 10 μL total volume cycle sequencing
reaction.
PCR reaction assembly
PCR reactions were assembled in a 384-well plate
(AB1111, Thermo Fisher Scientific Inc., Waltham, MA)
automatically using a Hamilton MicroLab StarPlus liquid
handling/pipetting system.
DNA extraction and distribution to 384-well plates
DNA was extracted and purified from saliva, blood or tis-
sue according to standard protocol from vendors (e.g.
Oragene™, DNA Genotek Inc., Ottawa, Ontario, Canada;
Gentra Puregene™, QIAGEN Inc. Valencia, CA). As cur-
rently configured, 16.0 μg is required to complete all five
tiers of testing. Genomic DNA was diluted first to 100 ng/
μL in nuclease free ddH2O and then to 10 ng/μL using 1×
PCR buffer.
The Hamilton MicroLab StarPlus distributed 3 μL of sam-
ple DNA to the appropriate wells of the 384-well PCR
plate that already contains assays in 1.5 μL glycerol (Addi-
tional files 44 and 45).
Master Mix preparation and distribution
A master mix was prepared consisting of 5.17 μL ddH2O
(nuclease free), 0.93 μL 10× buffer (0.5 M Tris HCl, 0.1 M
KCl, 0.05 M (NH4)2SO4 and 0.0208 M MgCl2 PH 8.1), 1.2
μL Bioline dNTPs 2.5 mM each dNTP (part number BIO-
39025 BioLine USA, Taunton, MA) and 0.2 μL Roche Fast-
Start™ polymerase 1 Unit (Part number 12 032 945 001
Roche Diagnostic GmbH, Mannheim, Germany) totalling
7.5 μL per 12 μL PCR reaction. PCR was performed in an
ABI 9700 thermal cycler under the following conditions:
initial denaturation and enzyme activation at 95.0°C for
1 cycle of 6 min, followed by 35 cycles of denaturation at
95.5°C for 55 s, annealing at 58.0°C for 30 s, and exten-
sion at 72.0°C for 55 s followed by a final single cycle
extension at 72.0°C for 7 min.
Post PCR processing
After PCR, the Hamilton MicroLab StarPlus added 5 μL of
1× PCR buffer to each well to ensure there was enough
volume for the QIAxcel system, and the 384-well plate
was distributed to four 96-well plates since the QIAxcel
system currently only handles 96-well plates. After visu-
ally searching the gel image or spreadsheet output of the
QIAxcel system to detect any deletions greater than 14 bp
or duplications greater than 14 bp (but less than PCR
product size), product concentrations were determined.
The Hamilton MicroLab StarPlus condensed the four
plates back to a 384-well plate for magnetic bead purifica-
tion and sequence reaction assembly. PCR purification
was per AMPure™ protocol (Agencourt Biosciences Corp.
Beverly, MA) slightly modified for the Hamilton robot.
Using concentration values from the QIAxcel system in
tab delimited format, PCR reactions were selectively
diluted by the Hamilton MicroLab StarPlus to achieveBMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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normalization of concentration to a range from 2 to 7 ng/
μL. Forward and reverse sequence reactions were assem-
bled separately in two 384-well plates. A 1/16th Big Dye™
(Applied Biosystems Inc. part of Life Technologies,
Carlsbad, CA) master mix was prepared using: 0.34 μL Big
Dye, and 2.41 μL 5× Big Dye Buffer. 2.75 μL master mix
was pipetted into the wells of the 384 well sequencing
plates which already contained the sequencing primer in
0.5 μL pure glycerol. Next 6.75 μL of the purified and nor-
malized PCR product were pipetted into the appropriate
wells. Cycle sequencing was performed on the 10.0 μL
sequencing reaction in an ABI 9700 thermal cycler under
an initial denaturation at 96.0°C for 4 min followed by 25
cycles of denaturation at 96.0°C for 10 s, annealing at
50.0°C for 5 s, and extension at 60.0°C for 4 min.
Sequence reaction purification was accomplished per
CleanSeq™ protocol (Agencourt Biosciences Corp. Bev-
erly, MA) also slightly modified for the Hamilton automa-
tion. After CleanSeq™, the purified sequencing product
plates were heat-sealed and installed in 3730 sequence
assembly plates (Applied Biosystems) with Direct Inject
Magnets (Agencourt) and loaded into the 3730 sequencer.
An ABI 3730 sequencer was used to perform the sequenc-
ing operation and Mutation Surveyor and/or SeqScape
and/or Sequencher applications were used to analyze the
resulting sequences and to search for variations from a
consensus sequence.
Cost Estimates
Table 8 presents an estimate of reagent and plastic costs
based on 12 uL PCR and 10 uL sequencing reaction vol-
umes.
One approach to pricing the service would be to average
the price per patient over a typical mix of 100 muscular
dystrophy patients across all five tiers of testing. Consum-
able material costs for MLPA (tier 1 = 2 MLPA kits) includ-
ing plastics and 20% waste are approximately $48.00
($24.00/kit) and for tier 5 including a much larger
number of reference samples is approximately $40.00 per
kit. Labor cost is estimated at 2 hours per patient of dedi-
cated technician time for tier 1, 8 hours per patient of one
technician for each tier 2-4 - primarily for sample process-
ing in steady state continuous mode - plus 8 hours per
patient of a second dedicated technician primarily for
sequence analysis, and finally 1 hour per patient per
MLPA kit for tier 5. Using those cost estimates, the per-
centage of DMD incidence (80%, use 60% to be conserv-
ative) versus total dystrophies and the percentage of large
deletion/duplication (60%) in DMD/BMD cases, and
$20.00/hour labor rate, average the direct cost per patient
over 100 patients as:
Consumable material costs:
Extract DNA from blood or saliva: 100 × $15.00/patient =
$1,500.00
Tier 1 (2-MLPA-rxns.): 100 × $48.00/patient = $4,800.00
Tier 2: 64 non DMD/BMD large del/dup × $532.00 Plate
1 = $34,048.00
Tier 3: 28 remaining undetected × $395.00 Plate 2 =
$11,060.00
Tier 4: 18 remaining undetected × $395.00 Plate 3 =
$7,110.00
Tier 5: 8 remaining undetected × $40.00 × 4 MLPA's =
$1,280.00
Total consumables = $59,798.00/100 = $600.00/patient
Add direct labor:
Extract DNA: 100 patients × 2 hrs./patient × $20.00/hr =
$4000.00
Tier 1: 100 patients × 2 hrs./patient × $20.00/hr. =
$4,000.00
Tier 2: 64 patients × 16 hrs./patient. × $20.00/hr. =
$20,480.00
Tier 3: 28 patients × 16 hrs./patient × $20.00/hr. =
$8,960.00
Tier 4: 18 patients × 16 hrs./patient × $20.00/hr. =
5,760.00
Tier 5: 8 patients × 5 hrs./patient × $20.00/hr. = $800.00
Total labor = $44,000.00/100 = $440.00/patient
Total consumables plus labor = $1040.00/patient
Add to this whatever your cost structure requires for indi-
rect/overhead including instrument maintenance costs+
profit + taxes = final price per patient direct cost. Even if
that final service pricing cannot be structured this way for
various reasons, these numbers still provide a good esti-
mate of the average cost per patient to the department.
Clinicians can significantly decrease the actual cost by
steering the molecular testing to a candidate gene based
on phenotype, clinical evaluations and any immunolabe-
ling data that has been prepared.BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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Quality Goals
Two quality goals were set for assays as follows: 1) No
known multiple nucleotide polymorphisms (MNPs) or
SNPs within primer sequences except rare SNPs allowed
in 5' half of primer. 2) A 12 μL PCR increased to 17 μL
with 1×-PCR buffer will have a single sharp band of the
planned size and a minimum concentration 0.5 ng/μL
(preferably > 2.0 ng/μL) when run on QIAxcel system
DNA analyzer (Figure 2).
Three goals were set for gene coverage as follows: 1) All
regions of interest will be covered. Regions of interest are
pre-defined for each gene and do vary but usually consist
of all coding and non-coding exons, splice sites, promot-
ers, 1000 bp of 5' UTR and 3000 bp of 3' UTR. 2) At least
95% of the total sequence for all regions of interest of a
given gene is covered by both the sense and anti-sense
sequencing reaction. Difficult regions to sequence such as
polynucleotide repeats and G/C rich areas will have mul-
tiple assays attempting to sequence through the region
and will have at least single-stranded coverage. 3) For any
given patient, the quality score for every pure (i.e.
homozygous) base (as calculated by SeqScape and based
on the quality scores of each strand running through that
base) for all bases except those in a very few clearly diffi-
cult to sequence regions must be greater than 25 on the 0-
50 scale used by SeqScape.
Patient materials and mutation reporting
This study was approved by the Children's Hospital Bos-
ton Institutional Review Board. Written informed consent
was obtained for each participant. Mutations found using
this process should be reported to the Leiden muscular
dystrophy pages with technique described as PCR, SEQ.
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[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S15.ctf]
Additional file 16
CAPN#-DB.pt. SeqScape™ template file for CAPN3. This file must be 
downloaded and saved (not opened) and the file name must be changed 
to add .pt at the end of the file name just before the .ctf extension.  For 
example, change file name from 1471-2156/10/66/suppl/S16.ctf to 
1471-2156/10/66/suppl/S16.pt.ctf. The file can then be successfully 
imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S16.ctf]
Additional file 17
DMD_RSS000009308V01_3730_01.pt. SeqScape™ template file for 
DMD. This file must be downloaded and saved (not opened) and the file 
name must be changed to add .pt at the end of the file name just before 
the .ctf extension.  For example, change file name from 1471-2156/10/
66/suppl/S17.ctf to 1471-2156/10/66/suppl/S17.pt.ctf. The file can then 
be successfully imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S17.ctf]
Additional file 18
FKRP_RSS000009239V01_3730_01.pt. SeqScape™ template file for 
FKRP. This file must be downloaded and saved (not opened) and the file 
name must be changed to add .pt at the end of the file name just before 
the .ctf extension.  For example, change file name from 1471-2156/10/
66/suppl/S18.ctf to 1471-2156/10/66/suppl/S18.pt.ctf. The file can then 
be successfully imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S18.ctf]
Additional file 19
LMNA.pt. SeqScape™ template file for LMNAThis file must be down-
loaded and saved (not opened) and the file name must be changed to add 
.pt at the end of the file name just before the .ctf extension.  For example, 
change file name from 1471-2156/10/66/suppl/S19.ctf to 1471-2156/
10/66/suppl/S19.pt.ctf. The file can then be successfully imported into the 
SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S19.ctf]BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
Page 16 of 18
(page number not for citation purposes)
Additional file 20
SGCA_103008.pt. SeqScape™ template file for SGCA. This file must be 
downloaded and saved (not opened) and the file name must be changed 
to add .pt at the end of the file name just before the .ctf extension.  For 
example, change file name from 1471-2156/10/66/suppl/S20.ctf to 
1471-2156/10/66/suppl/S20.pt.ctf. The file can then be successfully 
imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S20.ctf]
Additional file 21
SGCB_aug_0608.pt. SeqScape™ template file for SGCB. This file must 
be downloaded and saved (not opened) and the file name must be 
changed to add .pt at the end of the file name just before the .ctf extension.  
For example, change file name from 1471-2156/10/66/suppl/S21.ctf to 
1471-2156/10/66/suppl/S21.pt.ctf. The file can then be successfully 
imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S21.ctf]
Additional file 22
SGCD1 and D2Copy.pt. SeqScape™ template file for SGCD. This file 
must be downloaded and saved (not opened) and the file name must be 
changed to add .pt at the end of the file name just before the .ctf extension.  
For example, change file name from 1471-2156/10/66/suppl/S22.ctf to 
1471-2156/10/66/suppl/S22.pt.ctf. The file can then be successfully 
imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S22.ctf]
Additional file 23
SGCG-Dick051206.pt. SeqScape™ template file for SGCG. This file 
must be downloaded and saved (not opened) and the file name must be 
changed to add .pt at the end of the file name just before the .ctf extension.  
For example, change file name from 1471-2156/10/66/suppl/S23.ctf to 
1471-2156/10/66/suppl/S23.pt.ctf. The file can then be successfully 
imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S23.ctf]
Additional file 24
TRIM32.pt. SeqScape™ template file for TRIM32. This file must be down-
loaded and saved (not opened) and the file name must be changed to add 
.pt at the end of the file name just before the .ctf extension.  For example, 
change file name from 1471-2156/10/66/suppl/S24.ctf to 1471-2156/
10/66/suppl/S24.pt.ctf. The file can then be successfully imported into the 
SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S24.ctf]
Additional file 25
UCDSdisply_unk_var_only.ds. SeqScape™ template file for display set-
tings. This file must be downloaded and saved (not opened) and the file 
name must be changed to add .ds at the end of the file name just before 
the .ctf extension.  For example, change file name from 1471-2156/10/
66/suppl/S25.ctf to 1471-2156/10/66/suppl/S25.ds.ctf. The file can then 
be successfully imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S25.ctf]
Additional file 26
UCDSdmddefaults.ad. SeqScape™ template file for analysis defaults set-
tings. This file must be downloaded and saved (not opened) and the file 
name must be changed to add .ad at the end of the file name just before 
the .ctf extension.  For example, change file name from 1471-2156/10/
66/suppl/S26.ctf to 1471-2156/10/66/suppl/S26.ad.ctf. The file can 
then be successfully imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S26.ctf]
Additional file 27
UCDSprotocol1.ap. SeqScape™ template file for analysis protocol set-
tings. This file must be downloaded and saved (not opened) and the file 
name must be changed to add .ap at the end of the file name just before 
the .ctf extension.  For example, change file name from 1471-2156/10/
66/suppl/S27.ctf to 1471-2156/10/66/suppl/S27.ap.ctf. The file can then 
be successfully imported into the SeqScape application (ABI).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S27.ctf]
Additional file 28
384 welplate tier 2(plate1-DMD)_layout. Excel file shows the assay 
locations in DMD plate (plate 1).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S28.XLS]
Additional file 29
384 welplate tier 3(Plate2)_layout. Excel file that shows the assay loca-
tions in plate 2.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S29.XLS]
Additional file 30
384 welplate tier 4 (Plate3)_layout. Excel file that shows the assay loca-
tions in plate 3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S30.XLS]
Additional file 31
Plate1_assaysbox_EVENSlayout. Excel file that shows the even DMD 
assay locations in ScreenMate™ box 1
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2156-10-66-S31.XLS]BMC Genetics 2009, 10:66 http://www.biomedcentral.com/1471-2156/10/66
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Click here for file
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Additional file 33
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Click here for file
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to assay number.)
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[http://www.biomedcentral.com/content/supplementary/1471-
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